Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Menarini Hellas Α.Ε
Patmou 16-18
Marousi Attica
Ζip code 15123
Τel.: +30 210 8316111

• About Us
• History
• Products
• Menarini International

• Innovation & Research
• Careers
• News
• Fair Play Menarini

• Ethics and Compliance
• Contact Us
• Privacy

• Cookie Settings
• Pharmacovigilance
• Sitemap